From the prodromal stage of multiple sclerosis to disease prevention
Marrie R, Allegretta M, Barcellos L, Bebo B, Calabresi P, Correale J, Davis B, De Jager P, Gasperi C, Greenbaum C, Helme A, Hemmer B, Kanellis P, Kostich W, Landsman D, Lebrun-Frenay C, Makhani N, Munger K, Okuda D, Ontaneda D, Postuma R, Quandt J, Roman S, Saidha S, Sormani M, Strum J, Valentine P, Walton C, Zackowski K, Zhao Y, Tremlett H. From the prodromal stage of multiple sclerosis to disease prevention. Nature Reviews Neurology 2022, 18: 559-572. PMID: 35840705, DOI: 10.1038/s41582-022-00686-x.Peer-Reviewed Original ResearchConceptsMultiple sclerosisTrials of interventionsType 1 diabetes mellitusImmune-mediated diseasesStandard criteriaDiagnosis of MSStages of MSDisease frameworkIdentification of individualsProdromal stageMS prodromeDisease preventionProdromal MSStop progressionRheumatoid arthritisProdromeDiseaseDisease markersThe Multiple Sclerosis Prodrome: Evidence to Action
Tremlett H, Munger KL, Makhani N. The Multiple Sclerosis Prodrome: Evidence to Action. Frontiers In Neurology 2022, 12: 761408. PMID: 35173664, PMCID: PMC8841819, DOI: 10.3389/fneur.2021.761408.Peer-Reviewed Original ResearchMultiple sclerosisProdromal phaseEarly recognitionImproved disease courseProdromal multiple sclerosisImmune-mediated diseasesMultiple sclerosis prodromeEarly disease managementDisease courseProdromal featuresDefinitive diagnosisClassical diseaseGeneral populationMS prodromeDisease preventionProdromeMajor long-term implicationsDisease managementPrognosisDiseaseLong-term implicationsPreventionSclerosisEvidenceSymptoms